Grant M. Henning
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Grant M. Henning has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Abhinav Khanna
Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
3 shared publicationsEric H. Kim
Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, MO
3 shared publicationsStephen A. Boorjian
Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
3 shared publicationsEkamjit S. Deol
Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
2 shared publicationsGerald L. Andriole
Washington University School of Medicine, St. Louis, USA
2 shared publicationsJoel M. Vetter
Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, MO
2 shared publications
Latest Publications
- Open Access
- 1 May 2025
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 3 (5)
Editorial Comment: Urethral Adenocarcinoma: A Rare Malignancy With Poor Oncologic Outcomes Despite Neoadjuvant Treatment and Consolidative Therapy
- 1 May 2025
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 3 (5)
Open AccessEditorial Comment: Urethral Adenocarcinoma: A Rare Malignancy With Poor Oncologic Outcomes Despite Neoadjuvant Treatment and Consolidative Therapy
- 1 May 2025
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 12 (3) , 305-315
Trends in Outpatient Radical Prostatectomy and Same-Day Discharge for Prostate Cancer: Analysis of the National Inpatient Sample and Nationwide Ambulatory Surgery Sample
Interest has grown in optimizing radical prostatectomy (RP) pathways for prostate cancer (PCa) and RP has been removed from Centers for Medicare & Medicaid Services inpatient only list. We aim to determine national trends in outpatient RP. The National Inpatient Survey (NIS) and Nationwide Ambulatory Surgery Survey (NASS) were queried to categorize RPs between 2016-2020 as inpatient RP and outpatient RPs, comprising same day discharge (SDD) and ambulatory encounters. Trends in outpatient RP over time were analyzed. Multivariable logistic regression analysis identified factors associated with SDD. Multivariable generalized linear models were used to compare total hospital charges between SDD and inpatient RPs. In a cohort of 362,123 RPs from 2016-2020, outpatient RPs increased from 4.8% to 53.7% (p<0.01) and SDD increased from 0.03% to 2.0% (p<0.01). Minimally invasive surgery (OR 1.59, p<0.01), highest quartile annual hospital caseload (OR 1.98, p=0.01), and low hospital bed count (OR 1.96, p=0.03) were associated with SDD. <20% of centers utilized SDD, although a select few hospitals discharged over 50% of RPs the same day. Ambulatory ($63,060) and SDD ($63,332) RPs had lower total charges compared to inpatient RPs ($69,951). Multivariable analysis demonstrated that SDD was associated with a reduction in total charges (OR 0.88, p<0.01). Over 50% of RPs are now performed as ambulatory or SDD encounters. SDD RP is more common in high volume facilities with lower bed counts. Though our data suggest lower hospital charges, further study is warranted to evaluate the impact of SDD on readmission rates and direct patient costs.
- 1 May 2025
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 12 (3) , 305-315
Trends in Outpatient Radical Prostatectomy and Same-Day Discharge for Prostate Cancer: Analysis of the National Inpatient Sample and Nationwide Ambulatory Surgery Sample
Interest has grown in optimizing radical prostatectomy (RP) pathways for prostate cancer (PCa) and RP has been removed from Centers for Medicare & Medicaid Services inpatient only list. We aim to determine national trends in outpatient RP. The National Inpatient Survey (NIS) and Nationwide Ambulatory Surgery Survey (NASS) were queried to categorize RPs between 2016-2020 as inpatient RP and outpatient RPs, comprising same day discharge (SDD) and ambulatory encounters. Trends in outpatient RP over time were analyzed. Multivariable logistic regression analysis identified factors associated with SDD. Multivariable generalized linear models were used to compare total hospital charges between SDD and inpatient RPs. In a cohort of 362,123 RPs from 2016-2020, outpatient RPs increased from 4.8% to 53.7% (p<0.01) and SDD increased from 0.03% to 2.0% (p<0.01). Minimally invasive surgery (OR 1.59, p<0.01), highest quartile annual hospital caseload (OR 1.98, p=0.01), and low hospital bed count (OR 1.96, p=0.03) were associated with SDD. <20% of centers utilized SDD, although a select few hospitals discharged over 50% of RPs the same day. Ambulatory ($63,060) and SDD ($63,332) RPs had lower total charges compared to inpatient RPs ($69,951). Multivariable analysis demonstrated that SDD was associated with a reduction in total charges (OR 0.88, p<0.01). Over 50% of RPs are now performed as ambulatory or SDD encounters. SDD RP is more common in high volume facilities with lower bed counts. Though our data suggest lower hospital charges, further study is warranted to evaluate the impact of SDD on readmission rates and direct patient costs.
- Open Access
- 21 March 2025
- Published by Wiley in BJU International
- Vol. 136 (1) , 42-44
Assessing the efficacy and safety of sequential intravesical gemcitabine and docetaxel – does time from transurethral resection of bladder tumour to induction matter?
- 21 March 2025
- Published by Wiley in BJU International
- Vol. 136 (1) , 42-44
Open AccessAssessing the efficacy and safety of sequential intravesical gemcitabine and docetaxel – does time from transurethral resection of bladder tumour to induction matter?
- 20 September 2024
- Published by Elsevier in Journal of Surgical Education
- Vol. 81 (11) , 1743-1747
The Film Room: Using Artificial Intelligence to Facilitate Video Review for Urology Trainees
- 20 September 2024
- Published by Elsevier in Journal of Surgical Education
- Vol. 81 (11) , 1743-1747
The Film Room: Using Artificial Intelligence to Facilitate Video Review for Urology Trainees
- Open Access
- 1 April 2024
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 2 (4)
The Clinical Impact of the 4Kscore Test on Prostate Biopsy Decision Making in the Setting of MRI
Introduction: Biomarkers are often used in conjunction with MRI to improve the specificity of prostate cancer screening. Our objective was to evaluate the real-world utility of the 4Kscore test in the setting of MRI. We explored the association of the 4Kscore test with the decision to pursue prostate biopsy and its contribution to the accurate detection of clinically significant prostate cancer. Methods: We retrospectively analyzed patients undergoing the 4Kscore test and MRI for consideration of prostate biopsy. Multivariable logistic regression was used to model the association of 4Kscore with the decision to pursue biopsy. Receiver-operating characteristic curves were used to calculate the AUC of 4Kscore alone, PSA with MRI, and 4Kscore with MRI for detection of Gleason Grade Group ≥ 2 (GG ≥ 2) prostate cancer. Results: Of 442 patients, 311 (70%) proceeded to biopsy. 4Kscore was associated with the decision to pursue biopsy for continuous (odds ratio [OR] 1.05 per 1-point increase in 4Kscore, 95% confidence interval [CI] 1.02-1.07; P < .001) and categorical (high-risk 4Kscore: OR 16.1, 6.62-39.3, P < .001; intermediate-risk 4Kscore: OR 6.89, 95% CI 3.15-15.1; P < .01) models. For the detection of GG ≥ 2 prostate cancer, the AUC of 4Kscore with MRI (AUC = 0.866) was superior to 4Kscore alone (AUC = 0.800, P < .001) and PSA with MRI (AUC = 0.792, P < .001). Conclusions: In patients with MRI, the 4Kscore is associated with the decision to pursue prostate biopsy and augments the accurate prediction of GG ≥ 2 prostate cancer. Our findings suggest 4Kscore provides independent information as an adjunct to MRI for real-world clinical decision making.
- 1 April 2024
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 2 (4)
Open AccessThe Clinical Impact of the 4Kscore Test on Prostate Biopsy Decision Making in the Setting of MRI
Introduction: Biomarkers are often used in conjunction with MRI to improve the specificity of prostate cancer screening. Our objective was to evaluate the real-world utility of the 4Kscore test in the setting of MRI. We explored the association of the 4Kscore test with the decision to pursue prostate biopsy and its contribution to the accurate detection of clinically significant prostate cancer. Methods: We retrospectively analyzed patients undergoing the 4Kscore test and MRI for consideration of prostate biopsy. Multivariable logistic regression was used to model the association of 4Kscore with the decision to pursue biopsy. Receiver-operating characteristic curves were used to calculate the AUC of 4Kscore alone, PSA with MRI, and 4Kscore with MRI for detection of Gleason Grade Group ≥ 2 (GG ≥ 2) prostate cancer. Results: Of 442 patients, 311 (70%) proceeded to biopsy. 4Kscore was associated with the decision to pursue biopsy for continuous (odds ratio [OR] 1.05 per 1-point increase in 4Kscore, 95% confidence interval [CI] 1.02-1.07; P < .001) and categorical (high-risk 4Kscore: OR 16.1, 6.62-39.3, P < .001; intermediate-risk 4Kscore: OR 6.89, 95% CI 3.15-15.1; P < .01) models. For the detection of GG ≥ 2 prostate cancer, the AUC of 4Kscore with MRI (AUC = 0.866) was superior to 4Kscore alone (AUC = 0.800, P < .001) and PSA with MRI (AUC = 0.792, P < .001). Conclusions: In patients with MRI, the 4Kscore is associated with the decision to pursue prostate biopsy and augments the accurate prediction of GG ≥ 2 prostate cancer. Our findings suggest 4Kscore provides independent information as an adjunct to MRI for real-world clinical decision making.
- 31 May 2023
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 17 (5) , 2149-2155
Single-port vs multi-port robot-assisted renal surgery: analysis of perioperative outcomes for excision of high and low complexity renal masses
There is emerging but limited data assessing single-port (SP) robot-assisted surgery as an alternative to multi-port (MP) platforms. We compared perioperative outcomes between SP and MP robot-assisted approaches for excision of high and low complexity renal masses. Retrospective chart review was performed for patients undergoing robot-assisted partial or radical nephrectomy using the SP surgical system (n = 23) at our institution between November 2019 and November 2021. Renal masses were categorized as high complexity (7+) or low complexity (4–6) using the R.E.N.A.L. nephrometry scoring system. Adjusting for baseline characteristics, patients were matched using a prospectively maintained MP database in a 2:1 (MP:SP) ratio. For high complexity tumors (n = 12), SP surgery was associated with a significantly longer operative time compared to MP (248.4 vs 188.1 min, p = 0.02) but a significantly shorter length of stay (1.9 vs 2.8 days, p = 0.02). For low complexity tumors (n = 11), operative time (177.7 vs 161.4 min, p = 0.53), estimated blood loss (69.6.0 vs 142.0 mL, p = 0.62), and length of stay (1.6 vs 1.8 days, p = 0.528) were comparable between SP and MP approaches. Increasing nephrometry score was associated with a greater relative increase in operative time for SP compared to MP renal surgery (p = 0.07) using best of fit linear modeling. SP robot-assisted partial and radical nephrectomy is safe and feasible for low complexity renal masses. For high complexity renal masses, the SP system is associated with a significantly longer operative time compared to the MP technique. Careful consideration should be given when selecting patients for SP robot-assisted kidney surgery.
- 31 May 2023
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 17 (5) , 2149-2155
Single-port vs multi-port robot-assisted renal surgery: analysis of perioperative outcomes for excision of high and low complexity renal masses
There is emerging but limited data assessing single-port (SP) robot-assisted surgery as an alternative to multi-port (MP) platforms. We compared perioperative outcomes between SP and MP robot-assisted approaches for excision of high and low complexity renal masses. Retrospective chart review was performed for patients undergoing robot-assisted partial or radical nephrectomy using the SP surgical system (n = 23) at our institution between November 2019 and November 2021. Renal masses were categorized as high complexity (7+) or low complexity (4–6) using the R.E.N.A.L. nephrometry scoring system. Adjusting for baseline characteristics, patients were matched using a prospectively maintained MP database in a 2:1 (MP:SP) ratio. For high complexity tumors (n = 12), SP surgery was associated with a significantly longer operative time compared to MP (248.4 vs 188.1 min, p = 0.02) but a significantly shorter length of stay (1.9 vs 2.8 days, p = 0.02). For low complexity tumors (n = 11), operative time (177.7 vs 161.4 min, p = 0.53), estimated blood loss (69.6.0 vs 142.0 mL, p = 0.62), and length of stay (1.6 vs 1.8 days, p = 0.528) were comparable between SP and MP approaches. Increasing nephrometry score was associated with a greater relative increase in operative time for SP compared to MP renal surgery (p = 0.07) using best of fit linear modeling. SP robot-assisted partial and radical nephrectomy is safe and feasible for low complexity renal masses. For high complexity renal masses, the SP system is associated with a significantly longer operative time compared to the MP technique. Careful consideration should be given when selecting patients for SP robot-assisted kidney surgery.
- 4 March 2022
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 25 (2) , 180-186
Liquid biomarkers for early detection of prostate cancer and summary of available data for their use in African-American men
Background Several liquid biomarker tests have been developed to account for the limitations of prostate specific antigen (PSA) screening prior to prostate biopsy. African ancestry is an established risk factor for prostate cancer (PCa) and must be particularly considered when evaluating patients with liquid biomarkers. While multiple tests have been developed over decades of exploration, recent advances can help patients and physicians incorporate data into a broader clinical context. Methods We sought to review currently available liquid biomarker tests in a practical, clinically directed fashion with particular focus on performance in men with African ancestry. We reviewed discovery and validation studies and highlight important considerations for each test. Results We discuss the advantages and limitations of percent free PSA, Prostate Health Index, Progensa® PCA3, ExoDx® Prostate Test, SelectMDx®, 4Kscore® Test, and Mi-Prostate Score and summarize salient studies on their use. A literature review of evidence specifically for men with African ancestry was conducted and available studies were summarized. Conclusions Liquid biomarkers can be useful tools for aiding in risk stratification prior to prostate biopsy. Use of such tests should be individualized based on a thorough knowledge of supporting evidence and the goals of the patient and physician. Further study should prioritize evaluation of such biomarkers in men with African ancestry.
- 4 March 2022
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 25 (2) , 180-186
Liquid biomarkers for early detection of prostate cancer and summary of available data for their use in African-American men
Background Several liquid biomarker tests have been developed to account for the limitations of prostate specific antigen (PSA) screening prior to prostate biopsy. African ancestry is an established risk factor for prostate cancer (PCa) and must be particularly considered when evaluating patients with liquid biomarkers. While multiple tests have been developed over decades of exploration, recent advances can help patients and physicians incorporate data into a broader clinical context. Methods We sought to review currently available liquid biomarker tests in a practical, clinically directed fashion with particular focus on performance in men with African ancestry. We reviewed discovery and validation studies and highlight important considerations for each test. Results We discuss the advantages and limitations of percent free PSA, Prostate Health Index, Progensa® PCA3, ExoDx® Prostate Test, SelectMDx®, 4Kscore® Test, and Mi-Prostate Score and summarize salient studies on their use. A literature review of evidence specifically for men with African ancestry was conducted and available studies were summarized. Conclusions Liquid biomarkers can be useful tools for aiding in risk stratification prior to prostate biopsy. Use of such tests should be individualized based on a thorough knowledge of supporting evidence and the goals of the patient and physician. Further study should prioritize evaluation of such biomarkers in men with African ancestry.
- 1 June 2021
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 19 (3) , 194-198
Advances in Biomarkers for Detection, Surveillance, and Prognosis of Bladder Cancer
- 1 June 2021
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 19 (3) , 194-198
Advances in Biomarkers for Detection, Surveillance, and Prognosis of Bladder Cancer
- 1 April 2021
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 39 (4) , 234.e15-234.e19
Factors associated with higher prostate biopsy yield: when is software-assisted fusion MRI-targeting necessary?
- 1 April 2021
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 39 (4) , 234.e15-234.e19
Factors associated with higher prostate biopsy yield: when is software-assisted fusion MRI-targeting necessary?